Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
36
KPRX Quote, Financials, Valuation and Earnings
Last price:
$2.12
Seasonality move
:
2.34%
Day range:
$2.09 - $2.17
52-week range:
$1.76 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.35x
Volume:
50.6K
Avg. volume:
52.2K
1-year change:
-37.32%
Market cap:
$7.9M
Revenue:
$16M
EPS (TTM):
-$2.46
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Kiora Pharmaceuticals, Inc. has 411.63% upside to fair value with a price target of $11.00 per share.
KPRX vs. S&P 500
-
Over the past 5 trading days, Kiora Pharmaceuticals, Inc. has overperformed the S&P 500 by 14.23% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Kiora Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kiora Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Kiora Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Kiora Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Kiora Pharmaceuticals, Inc. reported earnings per share of $0.01.
Enterprise value:
-11.1M
EV / Invested capital:
-0.48x
Price / LTM sales:
--
EV / EBIT:
-3.09x
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1.10x
Price / Operating cash flow:
1.15x
Enterprise value / EBITDA:
-3.08x
Gross Profit (TTM):
-$106.7K
Return On Assets:
-25%
Net Income Margin (TTM):
--
Return On Equity:
-34.44%
Return On Invested Capital:
-34.13%
Operating Margin:
82.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $16M | -- | -- | -- | |
| Gross Profit | -$152.2K | $16M | -$106.7K | -$14.2K | -$38.2K | |
| Operating Income | -$9.4M | $6.1M | -$12.3M | -$2.7M | -$2.5M | |
| EBITDA | -$9.2M | $6.2M | -$12.2M | -$2.7M | -$2.5M | |
| Diluted EPS | -$36.66 | -$0.54 | -$2.46 | -$0.81 | $0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $11.9M | $6.6M | $7M | $31.7M | $22.7M | |
| Total Assets | $25.5M | $17.7M | $15.9M | $38.5M | $29.9M | |
| Current Liabilities | $2M | $3M | $2.1M | $3.5M | $2.6M | |
| Total Liabilities | $8.1M | $7.1M | $7.8M | $8.5M | $7.5M | |
| Total Equity | $17.3M | $10.5M | $8.1M | $30M | $22.4M | |
| Total Debt | $114.5K | $4.8K | -- | $39.2K | $248.2K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.1M | $8.2M | -$10M | $920.1K | -$1.3M | |
| Cash From Investing | -- | -$23.1M | $9.6M | -$1.9M | $5.7M | |
| Cash From Financing | $9.7M | $15M | $265.4K | -- | -- | |
| Free Cash Flow | -$9.1M | $8.2M | -$10M | $920.1K | -$1.3M | |
KPRX
Sector
Market Cap
$7.9M
$28.4M
Price % of 52-Week High
51.44%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-3.46%
-1.32%
1-Year Price Total Return
-37.32%
-22.19%
Beta (5-Year)
-0.753
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.94
200-day SMA
Sell
Level
$2.82
Bollinger Bands (100)
Sell
Level
2.24 - 2.86
Chaikin Money Flow
Buy
Level
5.8M
20-day SMA
Buy
Level
$2.06
Relative Strength Index (RSI14)
Buy
Level
50.62
ADX Line
Sell
Level
37.22
Williams %R
Sell
Level
-17.1858
50-day SMA
Sell
Level
$2.39
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
39.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.491)
Buy
CA Score
(Annual)
Level (0.878)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-3.7969)
Buy
Piotroski F Score
(Annual)
Level (9)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.
Stock Forecast FAQ
In the current month, KPRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KPRX average analyst price target in the past 3 months is $11.00.
-
Where Will Kiora Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kiora Pharmaceuticals, Inc. share price will rise to $11.00 per share over the next 12 months.
-
What Do Analysts Say About Kiora Pharmaceuticals, Inc.?
Analysts are divided on their view about Kiora Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kiora Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Kiora Pharmaceuticals, Inc.'s Price Target?
The price target for Kiora Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $11.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kiora Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of KPRX?
You can purchase shares of Kiora Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kiora Pharmaceuticals, Inc. shares.
-
What Is The Kiora Pharmaceuticals, Inc. Share Price Today?
Kiora Pharmaceuticals, Inc. was last trading at $2.12 per share. This represents the most recent stock quote for Kiora Pharmaceuticals, Inc.. Yesterday, Kiora Pharmaceuticals, Inc. closed at $2.15 per share.
-
How To Buy Kiora Pharmaceuticals, Inc. Stock Online?
In order to purchase Kiora Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KPRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KPRX
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
0.35x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
KPRX
Sector
Revenue growth
-100%
4.85%
Earnings growth
100.77%
11.15%
Revenue (5-year growth)
42.93%
6.45%
Earnings forecast
-$0.72
-$0.20
Profitability
KPRX
Sector
Profitability FY 2024
$16M
$3.6M
Return on invested capital
-34.13%
-30.98%
Return on assets
-25%
-27.62%
Return on equity
-34.44%
-36.69%
Earnings Date
Last Earnings Date
Mar
31
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
KPRX
Sector
Total cash
$19.4M
$27.2M
Short term investments
$23M
$25.7M
Total assets
$36.5M
$79.9M
Long term debt
$248.2K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
